Cargando…

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization

Detalles Bibliográficos
Autores principales:	Klastrup, Vibeke, Stærke, Nina Breinholt, Søgaard, Ole Schmeltz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288237/ https://www.ncbi.nlm.nih.gov/pubmed/35843563 http://dx.doi.org/10.1016/j.cmi.2022.06.032

Ejemplares similares

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response
por: Søgaard, Ole Schmeltz
Publicado: (2022)

Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis
por: Ostrowski, Sisse R., et al.
Publicado: (2021)

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study
por: Søgaard, Ole Schmeltz, et al.
Publicado: (2022)

Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa
por: Oboh, Mary Aigbiremo, et al.
Publicado: (2022)

Association of Self-reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE)
por: Bannister, Wendy P, et al.
Publicado: (2023)

Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections
por: Stærke, Nina Breinholt, et al.
Publicado: (2022)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Private aspects of heterologous immunity
por: Rehermann, Barbara, et al.
Publicado: (2005)

Deciphering the association between HIV-specific immunity and immune reconstitution
por: Søgaard, Ole S.
Publicado: (2021)

DC-based immunotherapy as strategy to purge the HIV reservoir?
por: Søgaard, Ole S.
Publicado: (2019)

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
por: Hvilsom, Caroline Thue, et al.
Publicado: (2021)

Polysaccharide Responsiveness Is Not Biased by Prior Pneumococcal-Conjugate Vaccination
por: Bernth-Jensen, Jens Magnus, et al.
Publicado: (2013)

A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization
por: Mattoo, Sameer-ul-Salam, et al.
Publicado: (2021)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

Accelerating into Immunization Agenda 2030 with momentum from China’s successful COVID-19 vaccination campaign during dynamic COVID Zero
por: Rodewald, Lance E.
Publicado: (2023)

Mass testing—An underexplored strategy for COVID-19 control
por: Shen, Mingwang, et al.
Publicado: (2021)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
por: Dietz, Lisa Loksø, et al.
Publicado: (2023)

Mass vaccination against COVID-19 may require replays of the polio vaccination drives
por: Rahi, Manju, et al.
Publicado: (2020)

Repurposing COVID-19 Drive-Through Testing Centers for Mass Vaccination
por: Kim, Edward
Publicado: (2020)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Beyond adaptive immunity: induction of trained immunity by COVID-19 adenoviral vaccines
por: Netea, Mihai G., et al.
Publicado: (2023)

The gift of preexisting immunity for developing an alternative vaccine strategy
por: Tran, Kim A., et al.
Publicado: (2023)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Operational research for the safe and effective design of COVID-19 mass vaccination centres
por: Wood, Richard M., et al.
Publicado: (2021)

Parental consent for vaccination of minors against COVID-19()
por: Shevzov-Zebrun, Nina, et al.
Publicado: (2021)

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic
por: Al-Samkari, Hanny
Publicado: (2023)

Safety monitoring of COVID-19 vaccines – Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs()
por: Kendal, Alan
Publicado: (2021)

Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts
por: Castro, Franz, et al.
Publicado: (2022)

Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations
por: Love, Ashley S., et al.
Publicado: (2021)

COVID-19 vaccine allocation: addressing the United Kingdom’s colour-blind strategy
por: Osama, Tasnime, et al.
Publicado: (2021)

Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs
por: Saltoğlu, Neşe, et al.
Publicado: (2022)

Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
por: Lee, Hye Kyung, et al.
Publicado: (2023)

COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
por: Roncati, Luca, et al.
Publicado: (2020)

Immune cells‐derived exosomes: A promising strategy for COVID‐19 treatment
por: Zhang, Zichen, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Heterologous vaccine regimens against COVID-19
por: Duarte-Salles, Talita, et al.
Publicado: (2021)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nh37itm2sag1he4a0s78tjie6j